경 흉부 심 초음파에 의한 폐동맥 수축의 마우스 모델에서 마우스 오른쪽 심실 구조 및 기능의 평가

Executive Industry Relevance

Non-invasive assessment of right ventricular structure and function is critical for de-risking cardiovascular target validation in pulmonary hypertension and heart failure research. This echocardiography-based method enables longitudinal monitoring of RV remodeling in murine models, supporting mechanistic insight and predictive confidence in early discovery. By providing reproducible hemodynamic and morphometric readouts, it facilitates go/no-go decisions in preclinical portfolio management.

Strategic Applications in Biopharma R&D

Early Discovery & Target Validation

• Scientific Value: Enables interrogation of therapeutic hypotheses by quantifying RV structural and functional responses to pulmonary artery constriction.
• Operational Value: Provides reliable, non-invasive measurements of RV wall thickness, chamber dimensions, and systolic function across multiple time points.
• Predictive Value: Supports biological de-risking through longitudinal tracking of RV adaptation and dysfunction in disease models.

Screening & Assay Development

• Assay Readiness: Establishes standardized acoustic windows (B-mode, M-mode, Color Doppler) for reproducible RV phenotyping in mice.
• Quantitative Outputs: Delivers measurable endpoints including fractional area change, fractional shortening, peak pressure gradient, and pulmonary artery peak velocity.
• Scalability: Compatible with high-frequency ultrasound systems, enabling integration into preclinical screening workflows.

Translational & Preclinical Research

• Disease Relevance: Models pulmonary artery hypertension-induced RV stress, aligning with clinical pathophysiology of right heart failure.
• Translational Continuity: Bridges discovery-phase target validation with preclinical efficacy assessment through non-invasive functional monitoring.
• Mechanistic De-risking: Allows correlation of RV hemodynamic changes with molecular or pharmacological interventions.

Pipeline & Workflow Integration

The method fits within the discovery-to-preclinical continuum, supporting target validation through hemodynamic phenotyping and enabling assay-ready models for compound testing.

• Discovery Biology: Facilitates hypothesis testing of RV-specific pathways by providing quantifiable functional and structural readouts.
• Screening: Delivers standardized, reproducible imaging outputs suitable for evaluating compound effects on RV function.
• Analytics: Generates quantitative metrics (e.g., fractional area change, pressure gradient) that support comparative analysis across experimental groups.
• Translational Research: Enables longitudinal assessment of RV dysfunction, supporting continuity from target engagement to preclinical outcome prediction.
• Enterprise Reuse: Represents a reusable imaging platform applicable across cardiovascular and pulmonary disease models.

Operational & Enterprise Impact

• Scientific Value: Enhances target validation confidence by reducing ambiguity in RV phenotypic assessment.
• Operational Value: Ensures reproducibility through standardized acquisition protocols and offline analysis workflows.
• Strategic Value: Improves capital efficiency by enabling early detection of RV toxicity or lack of efficacy.
• Portfolio Impact: Supports risk-adjusted advancement decisions via objective, longitudinal functional data.

Implementation Considerations

• Requires expertise in murine echocardiography and cardiac anatomy.
• Dependent on high-frequency ultrasound systems (e.g., 30–40 MHz transducers) for adequate resolution.
• Necessitates blinded image acquisition and analysis to minimize observer bias.
• Requires physiological maintenance of heart rate during imaging via appropriate anesthesia protocols.
• Limited by operator-dependent variability in acoustic window selection, necessitating training and standardization.

Biopharma FAQs